ClinicalTrials.gg

Program

QLS-111

A development code. Also written as “QLS-111 Ophthalmic Solution (0.015%)”, “QLS-111 Ophthalmic Solution (0.075%)” and “QLS-111-FDC”.

Its studies are mostly in Glaucoma, Open-Angle · Low Tension Glaucoma, led by Qlaris Bio.

Furthest: phase 3, since Jan 17, 20265 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qlaris Bio50 open or runningphase 3since Jan 17, 2026Aug 18, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2023First studies: 2 phase 2 studiesFirst studyNCT06030193, NCT06016972
  2. Jan 31, 2024Phase 2 study in Glaucoma, Open-AngleNCT06249152 · 36 enrolled · United States
  3. Dec 22, 2025Phase 2 study in Glaucoma, Open-AngleNCT07354477 · 9 enrolled · United States
  4. Jan 17, 2026Phase 3 study in Glaucoma, Open-AnglePhase 3 reachedNCT07354516 · 64 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07354516Glaucoma, Open-Angle · United States3CompletedJul 22, 202664
NCT07354477Glaucoma, Open-Angle · United States2CompletedOct 1, 20269
NCT06249152Glaucoma, Open-Angle · United States2CompletedDec 20, 202436
NCT06030193Low Tension Glaucoma · South Korea2CompletedFeb 23, 202637
NCT06016972Glaucoma, Open-Angle · United States2CompletedAug 20, 202463

How it is read

Names in the registry

  • “QLS-111 Ophthalmic Solution (0.015%)”, 1 entry
  • “QLS-111 Ophthalmic Solution (0.075%)”, 1 entry
  • “QLS-111-FDC”, 1 entry
  • “QLS-111 ophthalmic solution (0.015%)”, 1 entry
  • “Experimental: QLS-111 ophthalmic solution, (0.015%)”, 1 entry

Codes read as this program: QLS111.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.